Gapping down
In reaction to disappointing earnings/guidance: MFRM -1%
Select metals/mining stocks trading lower: HMY -4.1%, MT -3.9%, BBL -2%, FCX -2%, GOLD -1.9%, BHP -1.8%, GG -1.7%, RIO -1.4%, GDX -1.4%
Select oil/gas related names showing early weakness: SDRL -6.8%, CHK -5.3%, OAS -3.9%, RDS.A -3.3%, TOT -2.8%, BP -2.8%, KMI -2.1%, COP -2%, RIG -1.9%
Other news: THLD -70.4% (reports two Phase 3 studies evaluating evofosfamide did not meet primary endpoints), BLUE -31.3% (provided study updates at ASH), AGIO -16.1% (provided study updates at ASH), GBT -12.4% (provided study updates at ASH), CMG -9.1% ( Issues Sales and Earnings Warning after E.coli Incident), ALNY -2.7% (provided study updates at ASH), AVP -1.2% (cont pre-mkt vol)
Analyst comments: TC -25.3% (downgraded to Underperform at RBC Capital Mkts; tgt lowered to $0.30 ), VNR -2.7% (downgraded to Sell at Stifel; tgt $3 ), KBR -2.2% (downgraded to Sell from Neutral at Goldman ), PII -0.7% (downgraded to Neutral from Buy at UBS
)
In reaction to disappointing earnings/guidance: MFRM -1%
Select metals/mining stocks trading lower: HMY -4.1%, MT -3.9%, BBL -2%, FCX -2%, GOLD -1.9%, BHP -1.8%, GG -1.7%, RIO -1.4%, GDX -1.4%
Select oil/gas related names showing early weakness: SDRL -6.8%, CHK -5.3%, OAS -3.9%, RDS.A -3.3%, TOT -2.8%, BP -2.8%, KMI -2.1%, COP -2%, RIG -1.9%
Other news: THLD -70.4% (reports two Phase 3 studies evaluating evofosfamide did not meet primary endpoints), BLUE -31.3% (provided study updates at ASH), AGIO -16.1% (provided study updates at ASH), GBT -12.4% (provided study updates at ASH), CMG -9.1% ( Issues Sales and Earnings Warning after E.coli Incident), ALNY -2.7% (provided study updates at ASH), AVP -1.2% (cont pre-mkt vol)
Analyst comments: TC -25.3% (downgraded to Underperform at RBC Capital Mkts; tgt lowered to $0.30 ), VNR -2.7% (downgraded to Sell at Stifel; tgt $3 ), KBR -2.2% (downgraded to Sell from Neutral at Goldman ), PII -0.7% (downgraded to Neutral from Buy at UBS
)